COMMUNIQUÉS West-GlobeNewswire

Rein Therapeutics to Present Late-Breaking Poster at the European Respiratory Society (ERS) 2026 Congress
04/09/2026
AUSTIN, Texas, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines in orphan pulmonary and fibrosis [...]
Alumis to Participate in Upcoming September Investor Conferences
04/09/2026
SOUTH SAN FRANCISCO, Calif., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases [...]
Iovance Biotherapeutics to Present at Upcoming Conferences
04/09/2026
SAN CARLOS, Calif., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating [...]
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04/09/2026
DALLAS, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene [...]
Intellia Therapeutics to Present at Morgan Stanley 24th Annual Global Healthcare Conference
04/09/2026
CAMBRIDGE, Mass., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core [...]
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04/09/2026
PRINCETON, N.J., Sept. 04, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, [...]
Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant Exercise
04/09/2026
COPENHAGEN, Denmark, September 4, 2026 – Bavarian Nordic A/S (OMX: BAVA) announced today that the Company's share capital has been increased by nominally DKK 285,900 as a consequence of employees’ exercise of warrants. [...]
C4X Discovery to receive milestone payment for NRF2 exclusive worldwide license agreement
04/09/2026
4 September 2026 – C4X Discovery Holdings Ltd (“C4XD”), a pioneering Drug Discovery company, today announces that it will receive a $13 million milestone payment from AstraZeneca [LON: AZN], triggered by the entry of [...]
Tangram Therapeutics annonce le passage aux cohortes de patients dans l’essai de phase 1/2 RESTORE-MASH évaluant le TGM-312 et la nomination du Dr Sonya Montgomery au poste de directrice du développement
04/09/2026
LONDRES, 04 sept. 2026 (GLOBE NEWSWIRE) -- Tangram Therapeutics ( « Tangram » ), société spécialisée dans le développement de médicaments innovants fondés sur l’ARNi visant à améliorer de manière significative la vie [...]
Raeliva Announces Rebrand and Expansion of Online Wellness Platform Beyond GLP-1 Care
04/09/2026
SAN DIEGO, CA, Sept. 04, 2026 (GLOBE NEWSWIRE) -- After building its initial patient base through online GLP-1 care under the OnlineSemaglutide.org brand, telehealth provider Raeliva is entering its next chapter with an [...]
New Copenhagen facility to strengthen Europe's quantum manufacturing capabilities
04/09/2026
COPENHAGEN, Denmark, Sept. 04, 2026 (GLOBE NEWSWIRE) -- The state-of-the-art quantum facility will strengthen Europe’s ability to design, manufacture and scale next-generation quantum chips, helping to position the [...]
ONWARD Medical to Announce First-Half 2026 Results on September 9, 2026
04/09/2026
EINDHOVEN, the Netherlands, Sept. 04, 2026 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD – US ADR: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, function, and [...]
Persica Pharmaceuticals publishes new analyses of antibiotic exposure-response, reinforcing the scientific case for PP353 in vertebrogenic Lumbar Back Pain
04/09/2026
The publication builds on Phase 1b PP353 data published in The Lancet's eClinicalMedicine, further supporting the rationale for a targeted, non-opioid approach to vertebrogenic Lumbar Back Pain Manuscript has been [...]
102,000 Orion Corporation A shares converted into B shares
04/09/2026
ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE 4 SEPTEMBER 2026 at 9.00 EEST 102,000 Orion Corporation A shares converted into B shares In accordance with [...]
Achieve Life Sciences Announced Granting of New Hire Inducement Awards
03/09/2026
SEATTLE and VANCOUVER, British Columbia, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and [...]
Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
04/09/2026
–4-year data from the Phase 1/2a open-label extension (OLE) studies showed substantial and durable reductions in seizures and continuing improvements in cognition and behavior in patients treated with zorevunersen on [...]
Applied Biologics Achieves Key Preclinical Milestone in Disease-Modifying Osteoarthritis Gene Therapy Program
03/09/2026
Company demonstrates successful gene delivery and expression in human cartilage cells using internally designed gene therapy platform SCOTTSDALE, Ariz., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Applied Biologics, a [...]
Kamada Updates on Withholding Tax Procedures on Previously Announced Cash Dividend to Shareholders
03/09/2026
REHOVOT, Israel and HOBOKEN, N.J., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (the “Company”) (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for [...]
Arvinas to Participate in Upcoming Investor Conferences
03/09/2026
NEW HAVEN, Conn., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) (“Arvinas” or the “Company”), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation [...]

Pages